IceCure Highlights New Peer-Reviewed Journal Article in Leading Surgery Journal, Demonstrating Cryoablation's Advantages Over Radiofrequency Ablation for Early-Stage Breast Cancer
Rhea-AI Summary
IceCure Medical (NASDAQ: ICCM) highlighted a peer-reviewed article in the International Journal of Surgery showing clinical advantages of ProSense cryoablation over radiofrequency ablation (RFA) for early-stage breast cancer.
The publication reports high local control rates comparable to breast-conserving surgery, notes a 99.02% recurrence-free rate in over 600 cryoablation patients, and describes procedural benefits such as local anesthesia and visible ice-ball margins. IceCure will present at the 34th Japanese Breast Cancer Society meeting on June 25-27, 2026, as partner Terumo plans a ProSense regulatory submission to Japan's PMDA in the second half of 2026.
AI-generated analysis. Not financial advice.
Positive
- Peer-reviewed article in top-ranked International Journal of Surgery supports cryoablation for early-stage breast cancer
- Reported 99.02% recurrence-free rate in over 600 breast cancer cryoablation patients with follow-up up to 17 years
- Thermal ablation outcomes described as comparable to breast-conserving surgery in carefully selected small tumors
- Procedural advantages over RFA include local anesthesia and real-time visualization of the ice-ball margin
- Terumo expected to submit ProSense for PMDA regulatory approval in Japan in the second half of 2026
- U.S. FDA marketing authorization of ProSense for early-stage breast cancer cited as driving physician interest
Negative
- Regulatory approval for ProSense in breast cancer in Japan is still pending, with submission only expected in the second half of 2026
News Market Reaction – ICCM
On the day this news was published, ICCM gained 3.20%, reflecting a moderate positive market reaction. Argus tracked a peak move of +32.4% during that session. Our momentum scanner triggered 19 alerts that day, indicating notable trading interest and price volatility. This price movement added approximately $516K to the company's valuation, bringing the market cap to $16.64M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Peers on Argus
ICCM was up while only one peer in the momentum scanner (TELA) also moved higher and several close peers showed declines, indicating today’s strength appears primarily stock-specific rather than a broad medical-device move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jun 17 | Private placement | Positive | +200.5% | Premium-priced $5.5M private placement with single institutional healthcare investor. |
| Jun 17 | Commercial/FDA update | Positive | +200.5% | 70% growth in active U.S. commercial ProSense install base post-FDA authorization. |
| Jun 02 | Reverse share split | Negative | -30.9% | 1-for-30 reverse split to support regaining Nasdaq $1.00 minimum bid compliance. |
| May 19 | Clinical data update | Positive | +3.6% | New ProSense data in kidney and breast tumors presented at ECIO 2026. |
| May 13 | Listing compliance | Neutral | +1.7% | Nasdaq grants 180-day extension to regain $1.00 minimum bid compliance. |
ICCM has frequently shown sharp, directionally consistent moves following financing, FDA/commercial updates, and capital-structure news.
Regulatory & Risk Context
Short interest is elevated, suggesting positioning that can contribute to higher volatility and the potential for sharp squeezes or reversals around news and capital markets activity.
An effective Form F-3 shelf allows ICCM to issue up to $100,000,000 of securities over time, which can provide funding flexibility but may introduce dilution risk when utilized.
Market Pulse Summary
This announcement reinforces strong long-term cryoablation outcomes, including a 99.02% recurrence-free rate over 600 patients, and outlines a PMDA submission plan for the second half of 2026. Investors may watch how Japan’s regulators and clinicians translate this evidence into adoption amid active shelf capacity and elevated short interest.
Key Terms
cryoablation medical
radiofrequency ablation medical
breast-conserving surgery medical
ipsilateral breast tumor-free survival medical
local anesthesia medical
general anesthesia medical
AI-generated analysis. Not financial advice.
Published in the International Journal of Surgery, globally ranked in the top three among surgery journals, the article highlights strong clinical outcomes with ProSense® cryoablation and describes thermal ablation as a "beacon of hope for patients
IceCure preparing for the 2026 Japanese Breast Cancer Society meeting and planned regulatory submission for breast cancer in
Published in the International Journal of Surgery, the article highlights the growing body of peer-reviewed evidence supporting cryoablation as a minimally invasive treatment option for appropriately selected patients with early-stage breast cancer and outlines meaningful procedural advantages compared with RFA.
The International Journal of Surgery is one of the world's most prestigious peer-reviewed medical journals and currently ranked third in the world among surgical journals. The journal is highly regarded for publishing high-quality clinical research, reviews, and meta-analyses that influence surgical practice globally.
The article, titled "Thermal Ablation as a Minimally Invasive Alternative to Surgery for Primary Breast Cancer," was authored by leading Japanese breast cancer specialists Drs. Masato Takahashi, Takayuki Kinoshita and Eisuke Fukuma. Professor Fukuma, a highly regarded cryoablation expert and ProSense® user at Kameda Medical Center in
Key cryoablation advantages to RFA include:
- During the 2025 JBCS Conference, Professor Fukuma presented a recurrence free rate of
99.02% from over 600 breast cancer patients treated with cryoablation based on data collected with follow up of up to 17 years. The RAFAELO study on RFA discussed in the article reported a 5-year ipsilateral breast tumor-free survival rate of98.6% in 353 patients. InJapan the standard of care after BCS for invasive breast cancer (Stage I–II) is to undergo radiation therapy. - Cryoablation can be performed under local anesthesia as compared to RFA which requires general anesthesia.
- During the procedure, cryoablation allows flexible adjustment of the ice ball size and the ice ball margin is visible, whereas RFA is hard to control due to tissue resistance and the micro bubble is vaguely visible.
- Multiple studies and meta-analyses reviewed by the authors found no significant differences in local recurrence or overall survival between thermal ablation, including cryoablation and RFA, and BCS in carefully selected patients with tumors measuring 2 cm or less.
- The authors concluded, "Ultimately, thermal ablation holds promise as a beacon of hope for patients, offering surgeons a validated method to de-escalate treatment without compromising oncological safety, while providing vastly superior aesthetic results compared to conventional BCS".
"We believe the growing body of clinical evidence supporting cryoablation is accelerating physician interest worldwide, particularly following the
Terumo Corporation is expected to submit ProSense® for regulatory approval in breast cancer to
About ProSense®
The ProSense® Cryoablation System is the first and only medical device to receive FDA marketing authorization for the local treatment of low-risk breast cancer with adjuvant endocrine therapy for women aged 70 and above, including patients who are not suitable for surgical alternatives for breast cancer treatment. A full list of benefits and risks can be found on the Company's website.
ProSense® is a minimally invasive cryosurgical tool that provides the option to destroy tumors by freezing them. The system uniquely harnesses the power of liquid nitrogen to create large lethal zones for maximum efficacy in tumor destruction in benign and cancerous lesions, including in the breast, kidney, lung, and liver.
ProSense® enhances patient and provider value by accelerating recovery, reducing pain, surgical risks, and complications. With its easy, transportable design and liquid nitrogen utilization, ProSense® opens the door to fast and convenient office-based procedures for breast tumors.
About IceCure Medical
IceCure Medical (Nasdaq: ICCM) develops and markets advanced liquid-nitrogen-based cryoablation therapy systems for the destruction of tumors (benign and cancerous) by freezing, with the primary focus areas being breast, kidney, bone and lung cancer. Its minimally invasive technology is a safe and effective option to surgical tumor removal that is easily performed in a relatively short procedure. The Company's flagship ProSense® system is marketed and sold worldwide for the indications cleared and approved to date including in the U.S., Europe and Asia.
Forward Looking Statement
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates" and similar expressions or variations of such words are intended to identify forward-looking statements. For example, IceCure is using forward looking statements in this press release when it discusses: the potential advantages of ProSense® cryoablation as compared to RFA and BCS; the growing body of clinical evidence supporting cryoablation and its potential to accelerate physician interest worldwide; the Company's preparations to participate in the 34th Annual Meeting of the JBCS; Japan as an important market for ProSense®; the expected regulatory submission by Terumo Corporation to Japan's PMDA for approval of ProSense® for breast cancer in Japan and the timing of such submission; the potential use of international clinical data and Japanese physician experience in connection with such submission; and the Company's and Terumo's efforts to expand access to minimally invasive breast cancer treatment options for patients in Japan. Historical results of scientific research and clinical and preclinical trials do not guarantee that the conclusions of future research or trials will suggest identical or even similar conclusions. Important factors that could cause actual results, developments and business decisions to differ materially from those anticipated in these forward-looking statements include, among others: the Company's planned level of revenues and capital expenditures; the Company's available cash and its ability to obtain additional funding; the Company's ability to market and sell its products; legal and regulatory developments in the United States and other countries; the Company's ability to maintain its relationships with suppliers, distributors and other partners; the Company's ability to maintain or protect the validity of its patents and other intellectual property; the Company's ability to expose and educate medical professionals about its products; political, economic and military instability in the Middle East, specifically in Israel; as well as those factors set forth in the Risk Factors section of the Company's Annual Report on Form 20-F for the year ended December 31, 2025 filed with the United States Securities and Exchange Commission ("SEC") on March 17, 2026, and other documents filed with or furnished to the SEC which are available on the SEC's website, www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.
IR Contact:
Email: investors@icecure-medical.com
Meir Peleg, CFO
Phone: +1-888-902-5716
Logo: https://mma.prnewswire.com/media/2319310/IceCure_Medical_Logo.jpg
View original content:SOURCE IceCure Medical